Eli Lilly oral GLP-1 cuts body weight by 10%

Eli Lilly’s oral GLP-1, orforglipron, led to significant weight loss and blood sugar reductions in a late-stage clinical trial. 

In the phase 3 study, adults with obesity, were overweight and with Type 2 diabetes lost an average of 10.5% of their body weight after 72 weeks on the highest dose of orforglipron, according to an Aug. 26 news release from the drugmaker. The drug also showed reduced A1C levels by up to 2.8%, with 75% of patients at the highest dose seeing an A1C of 6.5% or lower. 

The trial met both its primary and secondary points across all three tested doses (6, 12 and 36 milligram). Cardiovascular risks including non-HDL cholesterol, systolic blood pressure and triglycerides also showed improvement. 

With the results from the trial, the drugmaker plans to pursue global regulatory submissions for the drug in late 2025, the release said. 

The post Eli Lilly oral GLP-1 cuts body weight by 10% appeared first on Becker’s Hospital Review | Healthcare News & Analysis.